Percutaneous coronary intervention (PCI) including stent implantation for the treatment of coronary lesions has been shown to improve patient functional status and outcome. 1, 2 The expanding use of PCI, coupled with refinements in technology including the introduction of drug-eluting stents (DESs) and more intensive adjunctive pharmacological treatment, resulted in treatment of complex coronary lesions and patients with a history of clinically significant cardiovascular disease and/or coexisting conditions. 3 The DESs have improved outcomes of PCI due to the reduced restenosis compared to bare-metal stents, especially in specific subgroups (ie, patients with diabetes mellitus); however, they also extended the period during which patients are at risk of stent thrombosis.
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The PCI is established as an invasive approach for the treatment of stable and unstable coronary syndromes. However, this procedure (balloon inflation and/or stenting) can potentiate a prothrombotic state around lesion areas leading to ischemic complications. 4, 5 Platelet aggregates can occur in response to PCI or spontaneous disruption of a vulnerable plaque. [6] [7] [8] In view of the central role of platelets in coronary thrombosis, and enhanced platelet activation after PCI, the choice and duration of concomitant pharmacological environment (dual or even triple antiplatelet therapy and/or anticoagulants) have become critical. [9] [10] [11] The PCI may be complicated by adverse cardiac events and a need for urgent revascularization, some of which are attributed to acute, subacute, or late stent thrombosis. 12, 13 Modulation of thrombotic and coagulation potential is a key factor in improving early (<30 days) clinical outcomes and in preventing complications related to PCI. [14] [15] [16] For more than a decade, the mainstay of antiplatelet therapy has been the combination of the cyclooxygenase 1 inhibitor aspirin and the adenosine diphosphate (ADP)-receptor P2Y12 antagonist clopidogrel. In the meantime, evidence has emerged regarding the inherent limitations of clopidogrel. The pharmacokinetic and pharmacodynamic effects of clopidogrel are variable and may be influenced by genetic polymorphisms, which translate into differential pharmacodynamic and therapeutic responses, leading to the concept of clopidogrel ''nonresponders.'' [17] [18] [19] Two newer oral ADP blockers, prasugrel and ticagrelor, are associated with less interpatient variability and more potent inhibition of platelet aggregation. [20] [21] [22] [23] Both prasugrel and ticagrelor have proven to be superior to clopidogrel in patients with an acute coronary syndrome who were undergoing PCI. In view of this evidence, the optimal combination and duration of dual antiplatelet treatment (DAPT) after coronary stenting is the subject of ongoing debate.
Prolonged DAPT with aspirin þ clopidogrel is considered of paramount importance to avoid late (>30 days) or even very late (>1 year) DES thrombosis. [11] [12] [13] While this recommendation is supported by several mechanistic investigations suggesting a delayed healing process or a prolonged inflammatory response of the vessel wall after DES implantation, clinical evidence is controversial. 12, 13 A number of recently published meta-analyses 24-30 of randomized trials (Table 1 ) have attempted to address these issues. The most recent meta-analysis by Verdoia et al 24 published in this issue of Angiology summarizes the available evidence from 11 randomized trials (32 372 patients). The authors conclude that short duration of DAPT (S-DAPT; 3-6 months) can be safely considered, whereas a long duration of DAPT (L-DAPT; 24-36 months) increases the risk of major bleeding complications. These findings should be interpreted in view of multiple almost concomitantly published meta-analyses in the field. As shown in Table 1 , a number of meta-analyses with differentiated inclusion criteria and statistical approaches (pairwise and network meta-analyses, individual patient-level data metaanalysis or hierarchical Bayesian) have been published by independent groups. Among these meta-analyses, diverse grouping criteria have been used to specify the use of S-DAPT and L-DAPT against the current recommendations of the American College of Cardiology Foundation/American Heart Association guidelines of 12-month DAPT. Short duration of DAPT was specified as 6 months or monotherapy with aspirin, whereas L-DAPT was specified as >12-month duration. Of note, different types of DESs (first vs second generation) were used in the individual randomized controlled trials; however, this aspect was considered only in 1 meta-analysis. 26 The intrinsic biocompatibility of each stent component may play a relevant role in long-term safety than the actual anti-intimal hyperplasia stent potency. Findings derived from studies comparing different durations of DAPT after stent implantation could therefore be adjusted for types of stents and anti-intimal hyperplasia stent potency to avoid potential confounders.
A common finding across the meta-analyses is the lower risk of stent thrombosis with the prolonged duration of DAPT, whereas S-DAPT was associated with a reduced risk of major bleeding as compared with 12-month or prolonged DAPT (Table 2) . Moreover, the results are also consistent for hard clinical outcomes, favoring L-DAPT for prevention of myocardial infarction and showing no difference in cardiovascular mortality. Finally, prolonged duration of DAPT was shown to increase the risk of overall mortality mainly due to noncardiovascular causes, a finding that was validated only in 3 of 10 meta-analyses. 24, 25, 28 Systematic reviews and meta-analyses are often considered as a high level in the hierarchy of evidence; however, multiple reviews from different groups on the same topic may conclude the same results, but discrepancies can ensue either at the level of the objective results or, more commonly, at the level of their interpretation. Moreover, concerns have been raised regarding overlapping or even redundant meta-analyses that could cause confusion or debates due to potential discrepancies. 34 In the case of DAPT, currently ongoing randomized trials that examine different DAPT durations and regimens may clarify the role of the newly introduced antiplatelet regimens and provide adequate data that will help update the previous meta-analyses. Current recommendations for prolonged DAPT need to be made with caution, given the bleeding risk and increased financial cost. Further studies are needed to confirm that clopidogrel discontinuation after 6 months is a risk factor for late or very late stent thrombosis or is associated with worse cardiovascular outcomes.
